Clinical trial
Gemcitabine in Ovarian Cancer
NCT00191334 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191334 |
|---|---|
| Title | Gemcitabine in Ovarian Cancer |
| Official title | Phase II Study of Gemcitabine Plus Cisplatin as First-Line Therapy in Patients With Epithelial Ovarian Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Cancer |
| Intervention type | Drug |
| Interventions | gemcitabine, cisplatin |
| Enrollment | 50 |
| Start date | Dec 1, 2004 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Mar 27, 2009 |
| Countries | Russia |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: